In this sense, WES with targeted gene analysis (e.g., SCN8A, KCNQ2) is an effective diagnostic tool for patients with epilepsies as it can influence anti-epileptic drug selection, adverse effect minimization and consideration for surgery, based on each patient’s genetic script37. The gene discussed is SCN8A; the disease is epilepsy.